Metastatic Squamous Neck Cancer with Occult Primary Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Options for Metastatic Squamous Neck Cancer with Occult Primary
A link to a list of current clinical trials is included for each treatment section. For some types or stages of cancer, there may not be any trials listed. Check with your doctor for clinical trials that are not listed here but may be right for you.Untreated Metastatic Squamous Neck Cancer with Occult PrimaryTreatment of untreated metastatic squamous neck cancer with occult primary may include the following:Radiation therapy.Surgery.Radiation therapy followed by surgery.A clinical trial of chemotherapy followed by radiation therapy.A clinical trial of chemotherapy given at the same time as hyperfractionated radiation therapy.Clinical trials of new treatments.Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with untreated metastatic squamous neck cancer with occult primary. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug.
Intraocular (Uveal) Melanoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment Option Overview
Role of ObservationIris melanomas have relatively good outcomes with a 5-year survival rate of more than 95%. They are predominantly of the spindle-cell type and are usually smaller in size than posterior melanomas because of earlier detection. Conservative management is generally advocated whenever possible, but surgical intervention may be justified with unequivocal tumor growth or with extensive disease at initial examination.The management of small choroidal melanomas is controversial, and it is not clear whether treatment of small tumors prevents metastasis. The natural history of small choroidal melanoma is poorly understood. Small, pigmented, choroidal lesions cannot always be differentiated reliably on examination. Growth is a presumed indicator of malignant potential. The likelihood of progression from the time of diagnosis to the time when tumor growth warrants treatment has not been well characterized. Some ophthalmologists advocate
Skin Cancer Prevention (PDQ®): Prevention - Health Professional Information [NCI] - Who is at Risk?
Note: Separate PDQ summaries on Skin Cancer Screening,Skin Cancer Treatment,and Levels of Evidence for Cancer Screening and Prevention Studies are also available. Individuals whose skin freckles,tans poorly,or burns easily after sun exposure are particularly susceptible to developing skin cancer.[ 1 ] Observational and analytic epidemiologic studies have consistently shown that increased ...
Skin Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - Description of the Evidence
BackgroundIncidence and mortalityThere are three main types of skin cancer:Basal cell carcinoma.Squamous cell carcinoma (together with basal cell carcinoma, this is referred to as nonmelanoma skin cancer).Melanoma.Basal cell carcinoma and squamous cell carcinoma are the most common forms of skin cancer but have substantially better prognoses than the less common, generally more aggressive melanoma.Nonmelanoma skin cancer is the most commonly occurring cancer in the United States. Its incidence appears to be increasing in some  but not all  areas of the United States. Overall U.S. incidence rates have likely been increasing for a number of years. At least some of this increase may be attributable to increasing skin cancer awareness and resulting increasing investigation and biopsy of skin lesions. A precise estimate of the total number and incidence rate of nonmelanoma skin cancer is not possible, because reporting to cancer registries is not required. However, based on
Skin Cancer Prevention (PDQ®): Prevention - Patient Information [NCI] - Get More Information From NCI
Call 1-800-4-CANCERFor more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.Chat online The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer. Write to usFor more information from the NCI, please write to this address:NCI Public Inquiries Office9609 Medical Center Dr. Room 2E532 MSC 9760Bethesda, MD 20892-9760Search the NCI Web siteThe NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support
Genetics of Skin Cancer (PDQ®): Genetics - Health Professional Information [NCI] - About This PDQ Summary
Purpose of This SummaryThis PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the genetics of skin cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.Reviewers and UpdatesThis summary is reviewed regularly and updated as necessary by the PDQ Cancer Genetics Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH). Board members review recently published articles each month to determine whether an article should:be discussed at a meeting,be cited with text, orreplace or update an existing article that is already cited.Changes to the summaries are made through a consensus process in which
Melanoma Treatment (PDQ®): Treatment - Patient Information [NCI] - Recurrent Melanoma
Recurrent melanoma is cancer that has recurred (come back) after it has been treated. The cancer may come back in the area where it first started or in other parts of the body, such as the lungs or liver.
Intraocular (Uveal) Melanoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - nci_ncicdr0000062916-nci-header
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Intraocular (Eye) Melanoma Treatment
Skin Cancer Screening (PDQ®): Screening - Patient Information [NCI] - General Information About Skin Cancer
Skin cancer is a disease in which malignant (cancer) cells form in the tissues of the skin.The skin is the body's largest organ. It protects against heat, sunlight, injury, and infection. Skin also helps control body temperature and stores water, fat, and vitamin D. The skin has several layers, but the two main layers are the epidermis (top or outer layer) and the dermis (lower or inner layer). Skin cancer begins in the epidermis, which is made up of three kinds of cells:Squamous cells: Thin, flat cells that form the top layer of the epidermis. Cancer that forms in squamous cells is called squamous cell carcinoma.Basal cells: Round cells under the squamous cells. Cancer that forms in basal cells is called basal cell carcinoma.Melanocytes: Found in the lower part of the epidermis, these cells make melanin, the pigment that gives skin its natural color. When skin is exposed to the sun, melanocytes make more pigment and cause the skin to tan, or darken. Cancer that forms in melanocytes
Melanoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage IV and Recurrent Melanoma
Stage IV melanoma is defined by the American Joint Committee on Cancer's TNM classification system:Any T, any N, M1Treatment Options for Patients With Stage IV and Recurrent MelanomaImmunotherapy.Checkpoint inhibitors.Interleukin-2 (IL-2).Signal transduction inhibitors.BRAF (V-raf murine sarcoma viral oncogene homolog B1) inhibitors (for patients who test positive for the BRAF V600 mutation).MEK inhibitors.Multikinase inhibitors.KIT inhibitors.Chemotherapy.Palliative local therapy.Clinical trials should be strongly considered because of the rapid advances in the development of novel agents and combinations of agents designed to reverse or interrupt aberrant molecular pathways that support tumor growth.Treatment option overview for patients with stage IV and recurrent melanomaAlthough melanoma that has spread to distant sites is rarely curable, two approaches have demonstrated clinical benefit by prolonging overall survival (OS) in randomized trials: